News & Education
United Theranostics Is Redefining Cancer Treatment Through Precision Radiopharmaceutical Therapy
United Theranostics Featured in Meditech Today
United Theranostics was recently highlighted by Meditech Today for its pioneering work in advanced cancer care. The article showcases our leadership in targeted radiopharmaceutical therapy and molecular imaging, emphasizing our mission to deliver precise, personalized treatment options for patients with metastatic and thyroid cancers.
Read how United Theranostics is redefining cancer treatment and improving patient outcomes through innovation and compassion.
United Theranostics Secures $15 Million Senior Debt Facility to Fuel Network Growth and Expans
Minneapolis, MN — Feb. 11, 2025 – United Theranostics, a leading provider of radiopharmaceutical therapy and supportive molecular imaging for cancer treatment, is pleased to announce it successfully closed a $15 million senior debt facility with Old National Bank...
Princeton Press Release
United Theranostics Parent, LLC (“United Theranostics” or the “Company”), a leader in radiopharmaceutical therapy and supportive molecular imaging for cancer treatment, is pleased to announce the opening of United Theranostics – Princeton. United Theranostics –...
United Theranostics Appoints Rob Cherney as CEO to Lead Its Radiopharmaceutical Therapy and Supportive Molecular Imaging Business
Minneapolis, MN, September 17, 2024 – United Theranostics Parent, LLC (“United Theranostics” or the “Company”), a leader in radiopharmaceutical therapy and supportive molecular imaging for cancer treatment, is pleased to announce the appointment of Rob Cherney as its...
Dr. Munir Ghesani joins United Theranostics as Chief Medical Officer
United Theranostics, the leader in outpatient radiopharmaceutical therapy and imaging services, is pleased to announce that Dr. Munir Ghesani, MD, FACNM, FACR, FSNMMI, is joining United Theranostics as Chief Medical Officer effective June 1, 2024. Dr. Ghesani has...